Sex-specific associations between body mass index, Waist circumference and the risk of Barrett's oesophagus: A pooled analysis from the international BEACON consortium

Gut

Volumn 62, Issue 12, 2013, Pages 1684-1691

  Kubo, Ai ^a   Cook, Michael Blaise ^b   Shaheen, Nicholas J ^c   Vaughan, Thomas L ^d   Whiteman, David C ^e   Murray, Liam ^f   Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f School of Medicine   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CASE CONTROL STUDY; GASTROESOPHAGEAL REFLUX; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

BARRETT'S OESOPHAGUS; GASTROESOPHAGEAL REFLUX DISEASE; NUTRITION; OBESITY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BODY MASS INDEX; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; SEX FACTORS; WAIST CIRCUMFERENCE;

EID: 84887491918     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303753     Document Type: Article

References (48)

1. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993;270:1320.
2. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
3. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 Suppl.15):2-8.
4. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99:582-8.
5. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
6. Fennerty MB. Barrett's-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials? Gastroenterology 2002;122:1172-5.
7. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
8. Reid BJ, Barrett MT, Galipeau PC, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev 1996;5(Suppl.2):57-65.
9. Reid BJ, Li X, Galipeau PC, et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87-101.
10. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-6.
11. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-13.
12. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44; quiz e232.
13. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49.
14. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005;162:1050-61.
15. Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 2007;56:756-62.
16. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8.
17. Smith KJ, O'Brien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:2481-6.
18. Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
19. Veugelers PJ, Porter GA, Guernsey DL, et al. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006;19:321-8.
20. Olsen CM, Pandeya N, Green AC, et al. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am J Epidemiol 2011;174:582-90.
21. Beddy P, Howard J, McMahon C, et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 2010;97:1028-34.
22. El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151-6.
23. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41; quiz 311.
24. Ford ES, Li C, Zhao G, et al. Trends in obesity and abdominal obesity among adults in the United States from 1999-2008. Int J Obes (Lond) October 2012;7:10:e48528.
25. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41.
26. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133:403-11.
27. Obesity. Geneva: World Health Organization, 2009. http://www.who.int/gho/ ncd/risk-factors/bmi-text/en/index.html, (accessed oct 2012).
28. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
29. Petitti D. Meta-analysis decision analysis and cost-effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 2000.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
31. Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and esophageal adenocarcinoma consortium. Gastroenterology 2012;142:744-53. doi: 10.1053/j.gastro.2011.12.049. Epub 2012 Jan 11.
32. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:2619-28.
33. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211.
34. de Vries DR, van Herwaarden MA, Smout AJ, et al. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol 2008;103:1349-54.
35. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007;17:319-26.
36. Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 2010;20:41-8.
37. Hsu IR, Kim SP, Kabir M, et al. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007;86:s867-71.
38. Nagel G, Concin H, Bjorge T, et al. Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can). Ann Oncol 2011;22(6):1339-45.
39. Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011;13:R34.
40. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009;7:279-88.
41. Rosato V, Tavani A, Bosetti C, et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 2011 Oct; 60(10):1372-8.
42. Zhou P, Lv GQ, Wang JZ, et al. The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis. PLoS One 2011;6:e22092.
43. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009;115:86-96.
44. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-17.
45. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 2010;10:509-19.
46. Yamamoto S, Nakagawa T, Matsushita Y, et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care 2010;33:184-9.
47. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6.
48. Rothman K, Greenland S, Lash T. Modern epidemiology. 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008.